Clinical Trial Update: Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos [Phase 2]

View source ↗

Summary

Phase 2 randomized and open-label trial comparing DBI-102 to vehicle and hydroquinone for safety and efficacy in skin hyperpigmentation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperpigmentation

Drugs mentioned

• DBI-102
• Hydroquinone (hydroquinone)

Snippet

Sponsor: DermBiont, Inc. | Conditions: Hyperpigmentation | Phase 2 | Status: COMPLETED